Aussie Scientists Cast Doubt on Low-efficacy Astrazeneca Coronavirus Vaccine

(Ramon Tomey) A group of Australian scientists called on the country’s federal government to review its use of AstraZeneca’s coronavirus (COVID-19) vaccine. They argued that the jab is ineffective at generating herd immunity and has a low efficacy rate. However, the central government has rejected the proposal to pause the rollout scheduled next month.

Related Communist China Successfully Infiltrated Vaccine Giants Pfizer, Astrazeneca and Glaxosmithkline as Part of “Unrestricted Warfare” to Defeat the Us Military and Conquer North America

Source – Natural News

by Ramon Tomey, February 2nd, 2021

The opposition Labor Party and some immunologists have called on the Australian government to procure additional doses of the Pfizer/BioNTech and Moderna vaccines. Clinical trials for these two vaccines have shown that they have higher efficacy rates than the one produced by AstraZeneca.

“Until we get more data [showing] that AstraZeneca is as good as the others, the scientific and medical risk that you take is that you won’t get herd immunity,” said Australian Medical Association in Western Australia (AMA-WA) President Andrew Miller. He also warned that there could be a political risk for having a good vaccine for the rich and a not-so-good vaccine for the poor.

To avoid these risks, Miller said Australia should halt the planned rollout and source the best vaccines available to build public confidence.

However, the central government in Canberra said the AstraZeneca vaccine – developed in partnership with the University of Oxford – would provide vital protection against the Wuhan coronavirus. Australia’s Chief Medical Officer Paul Kelly said that the AstraZeneca vaccine is effective, safe and high-quality, and will be available in the country once the Australian Therapeutic Goods Administration approves it in February.

The British drug maker has agreed to supply Australia with 53 million vaccine doses, which, according to clinical trials, has a 70 percent efficacy rate. Australia has also ordered 10 million doses of the Pfizer/BioNTech vaccine – to be approved by the Australian regulator next month.

Some scientists have expressed concern over Canberra’s reliance on inaccurate AstraZeneca vaccine data

Back in November 2020, a scientist-turned-writer pointed out the “shaky science” behind the AstraZeneca vaccine data. In a piece for Wired magazine, Hilda Bastian highlighted many issues with the so-called “promising results” released by the drug maker.

Bastian pointed out that a “dosing error,” which was never explained, allowed the company to report a higher efficacy rate for their vaccine. Two standard doses of AstraZeneca’s Wuhan coronavirus jab achieved a 62 percent efficacy rate. However, volunteers given an initial half-dose and a subsequent full dose reported a higher efficacy rate of 90 percent. Bastian noted that AstraZeneca’s clinical trials were designed to examine the effect of the standard two-dose regimen, not the accidental dosing.

In addition, Bastian noted that AstraZeneca’s data came from two separate studies. These studies – one published in May 2020 and another at the end of June 2020 – were substantially different from each other. “The fact that they may have had to combine data from [these] two trials in order to get a strong result raises … [a] red flag,” she commented.

A number of Australian scientists have expressed concern about the central government’s reliance on the AstraZeneca jab, including Australian and New Zealand Society for Immunology (ASI) President Stephen Turner.

The ASI president said shifting to higher-efficacy vaccines “looks like a good idea in an ideal situation.” He added that a review of Australia’s vaccine strategy would be appropriate. However, procuring and rolling out the Pfizer/BioNTech vaccine also presents challenges as it needs to be stored at a temperature of -70 degrees Celsius.

Turner nevertheless remarked that the AstraZeneca jab could be a useful tool in the short term. The vaccine can be kept at temperatures between two to eight degrees Celsius, eliminating the need for specialized facilities. Aside from the lower temperatures needed for storage, AstraZeneca’s vaccine also has the lowest price compared to the Pfizer/BioNTech and Moderna candidates.

Despite its reported advantages, the AstraZeneca vaccine hit multiple roadblocks in earlier clinical trials. Last September, two participants were reported to have experienced spinal inflammation after receiving the shot, while a third participant died during clinical trials in Brazil a month later. Further investigation revealed that toxic ingredients in the jab, such as aborted human fetal tissue, contributed to the adverse effects associated with the vaccine.

Stillness in the Storm Editor: Why did we post this?

The news is important to all people because it is where we come to know new things about the world, which leads to the development of more life goals that lead to life wisdom. The news also serves as a social connection tool, as we tend to relate to those who know about and believe the things we do. With the power of an open truth-seeking mind in hand, the individual can grow wise and the collective can prosper.

– Justin

Not sure how to make sense of this? Want to learn how to discern like a pro? Read this essential guide to discernment, analysis of claims, and understanding the truth in a world of deception: 4 Key Steps of Discernment – Advanced Truth-Seeking Tools.

---

Stillness in the Storm Editor’s note: Did you find a spelling error or grammatical mistake? Send an email to corrections@stillnessinthestorm.com, with the error and suggested correction, along with the headline and url. Do you think this article needs an update? Or do you just have some feedback? Send us an email at sitsshow@gmail.com. Thank you for reading.

Source:

https://www.naturalnews.com/2021-02-02-aussie-scientists-cast-doubt-on-astrazeneca-vaccine.html